Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful efficacy in clinical trials. We evaluated the unifying characteristics of anti-amyloid agents wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolar, Martin, Abushakra, Susan, Hey, John A., Porsteinsson, Anton, Sabbagh, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424995/
https://www.ncbi.nlm.nih.gov/pubmed/32787971
http://dx.doi.org/10.1186/s13195-020-00663-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424995/
https://www.ncbi.nlm.nih.gov/pubmed/32787971
http://dx.doi.org/10.1186/s13195-020-00663-w

Ejemplares similares